Atlas Trials

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Clinical trial NCT03788291 · COMPLETED

Trial details

NCT number
NCT03788291
Sponsor
University of Rochester
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Start date
2019-03-25
Primary completion
2023-05-19
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.